Source comparison
CJC-1295 No DAC vs DAC: Dosing Protocol Differences
The presence or absence of Drug Affinity Complex fundamentally changes how CJC-1295 behaves in vivo. DAC is a synthetic modification that binds to serum albumin, extending the peptide's half-life from 30 minutes to approximately eight days. This allows once-we
This comparison does not assign a generated winner or score.
- The presence or absence of Drug Affinity Complex fundamentally changes how CJC-1295 behaves in vivo. DAC is a synthetic modification that binds to serum albumin, extending the peptide's half-life from 30 minutes to approximately eight days. This allows once-weekly dosing. Convenient for human therapeutic applications but problematic for research models aiming to replicate natural GH dynamics. CJC-1295 with DAC produces sustained elevation of baseline GH levels rather than pulsatile peaks, which over time can trigger compensatory downregulation of GH receptors in target tissues (liver, muscle, adipose) and suppression of endogenous GHRH secretion.
- CJC-1295 no DAC avoids this feedback loop entirely because the peptide clears the system before sustained receptor occupancy occurs. Each injection creates a transient amplification of the next natural pulse, then disappears. This preserves the body's ability to regulate its own GH secretion patterns. The pituitary remains responsive to physiological cues like sleep stage, glucose availability, and exercise intensity. From a research perspective, that's critical. It means the peptide augments normal physiology rather than overriding it.
- Standard dosing for DAC-modified CJC-1295 is 1–2 mg once weekly. For the no DAC version, the equivalent total weekly dose (100 mcg × 3 × 7 = 2,100 mcg or approximately 2 mg) is distributed across 21 smaller injections instead of one large bolus. The molecular outcome differs significantly: DAC protocols produce steady-state GH elevation averaging 2–4 ng/mL above baseline throughout the week, while no DAC protocols generate acute peaks of 8–15 ng/mL that return to baseline between doses. Animal models examining muscle protein synthesis, lipolysis, and IGF-1 secretion show superior tissue-level outcomes with pulsatile protocols compared to sustained elevation at equivalent total peptide exposure.